Amarillo Biosciences is developing a patented formulation of oral interferon-alpha that is safer and less expensive than injectable formulations. It is working with global partners like HELIXOR in Germany, Pharma Base in Switzerland, and Cymbiotics in the US to conduct clinical studies on using low-dose oral interferon-alpha to treat diseases like influenza and hepatitis C. HELIXOR produces mistletoe medical products using gentle manufacturing methods. Pharma Base has manufacturing plants in India and offices in the US and Switzerland. Cymbiotics focuses on transdermal drugs and therapeutic cosmetics products for pain, dermatology, diabetes, and cosmetics.